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Abstract
Background: Current clinical therapy of non-small cell lung cancer depends on histo-pathological classification. This
approach poorly predicts clinical outcome for individual patients. Gene expression profiling holds promise to improve
clinical stratification, thus paving the way for individualized therapy.
Methodology and Principal Findings: A genome-wide gene expression analysis was performed on a cohort of 91 patients.
We used 91 tumor- and 65 adjacent normal lung tissue samples. We defined sets of predictor genes (probe sets) with the
expression profiles. The power of predictor genes was evaluated using an independent cohort of 96 non-small cell lung
cancer- and 6 normal lung samples. We identified a tumor signature of 5 genes that aggregates the 156 tumor and normal
samples into the expected groups. We also identified a histology signature of 75 genes, which classifies the samples in the
major histological subtypes of non-small cell lung cancer. Correlation analysis identified 17 genes which showed the best
association with post-surgery survival time. This signature was used for stratification of all patients in two risk groups.
Kaplan-Meier survival curves show that the two groups display a significant difference in post-surgery survival time
(p=5.6E-6). The performance of the signatures was validated using a patient cohort of similar size (Duke University, n=96).
Compared to previously published prognostic signatures for NSCLC, the 17 gene signature performed well on these two
cohorts.
Conclusions: The gene signatures identified are promising tools for histo-pathological classification of non-small cell lung
cancer, and may improve the prediction of clinical outcome.
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Introduction
Lung cancer is the most frequent cause of cancer deaths in the
North America and Europe. In Europe alone, there were 386,300
new lung cancer cases in 2006, with an estimated 334,800 deaths.
This accounts for 13.5% of all cancer deaths [1]. Based on histo-
pathological presentation, lung cancer is sub-divided into four major
histological subtypes: small cell lung cancer (SCLC), squamous cell
carcinoma (SCC), adenocarcinoma (ADC), and large cell carcinoma
(LCC). The latter three, collectively referred to as non-small cell lung
cancer (NSCLC), account for almost 80% of lung cancers [2]. At
present, treatment of NSCLC is based on histo-pathological features
andstaging.However,pathologicallysimilartumorswithcomparable
stage show dramatically different response to the same therapy.
Common features at the molecular level may be able to predict such
outcome discrepancies among patients more reliably. For instance,
the efficacy of epidermal growth factor receptor (EGFR) antagonists
has been shown to depend on expression of its target -EGFR- in the
tumor [3]. Also, the beneficial effect of chemotherapies might depend
on the expression of certain proteins such as thymidine synthetase for
Pemetrexed [4]. Thus, improved classification of NSCLC is of
considerable clinical interest.
Recent advances in microarray technology enable researchers
to recapitulate molecular properties of NSCLC at the level of
individual genes [5,6,7,8,9]. However, the reproducibility of gene
expression signatures to predict high-risk of relapse or recurrence
is rarely reported. Therefore, it is highly desirable to identify
molecular classifiers that can reliably predict specific subgroups of
high- and low-risk patients. This would be helpful to select the
most appropriate therapy for individual patients.
In this study, we performed gene expression profiling on
NSCLC tumors and simultaneously collected normal lung tissue
samples in order to determine histo-pathological classifier genes
and high-risk index genes.
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A detailed description is provided in File S1.
Patient enrolment
Ninety-one NSCLC patients treated at the Erasmus MC
were included in this study. The written consent from all
participants involved in this study was obtained. Patient and
tumor characteristics are listed in Table 1. Tissues were
studied under an anonymous tissue protocol approved by the
medical ethical committee of Erasmus University Medical
Center.
We used two independent validation sets: 6 normal lung tissues
from GSE3526, and NSCLC samples from the Duke University
cohort [10].
Pathological analysis
Tumor samples were typed by two independent routine
pathological reviews, according to WHO guidelines [11].
Histochemical stains (periodic acid-Schiff and Alcian blue for
mucin) were applied when considered appropriate.
RNA Isolation and gene expression profiling
Dissected tumors and adjacent normal tissue were snap-frozen in
liquid nitrogen precooled isopentane within two hours after surgical
resection, and stored at 2196uCo r280uC until RNA extraction. 5
ı `g of total RNA was processed for analysis on Affymetrix U133 plus
2.0 arrays using standard protocols. The complete microarray data
is MIAME compliant and deposited in a MIAME compliant
database, Gene Expression Omnibus database at www.ncbi.nlm.
nih.gov/geo/info/linking.html (GSE19188).
Table 1. Characteristics of patients and samples.
Training set Validation set
(N=80) (N=76)
Heath 36 29
Tumor 44 47
Mean age (years) 62.3610.81 63.5610.73
Sex-% Female 27 34
Male 73 66
Race-% Caucasian 90 89
other 5 3
unknown 5 8
Tobacco history-% None - -
#30 yr 20 24
31–49 yr 20 18
$50 yr 18 18
unknown 41 39
Tumor type (n) Path. Review 1st 2
nd consistent 1st 2nd consistent
ADC 19 14 14 13 10 8
S C C 1 68 8 1 18 8
LCC 7 13 6 6 11 3
other 2 9 1 8 9 1
unknown 0 0 9 9
Stage-% Path. Review 1st 1st
IA 18 16
IB 45 42
IIA 2 -
IIB 30 21
IIIA 2 16
IIIB - -
IV 2 5
Status-% Alive 34 29
Deceased 61 63
unknown 5 8
Cause of death-% Lung cancer 27 34
other 18 18
unknown 55 47
doi:10.1371/journal.pone.0010312.t001
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Multiple parameters were used to control the overall quality of
arrays. The final intensity value of probe sets was summarized as
the deviation to the geometric mean of that probe set among all
arrays. Uninformative probe sets were eliminated and the
remaining probe sets were used for subsequent analyses.
Class comparison
Two-group comparisons were performed by Significance
Analysis of Microarrays [12]. This supervised analysis correlates
gene expression with a clinical variable based on a score calculated
using the change in expression and the standard deviation across
all samples.
Class prediction
All identified signatures were subjected to identify subgroups of
genes that maintain the capacity of the complete signatures in
distinguishing different groups maximally [13]. The performance
of optimized signatures was validated by ‘‘leave-one-out’’ cross
validation within the training set firstly, then with the validation set
[14]. Hierarchical clustering was performed using the Spotfire
Decision Site.
Survival analysis
We developed a step-wise approach based on gene expression
profiles to classify NSCLC with respect to prognostic outcome.
Firstly, the Wald test in the Cox proportional hazards model was
used to identify prognostic probe-sets which were the most likely
associated with overall survival [15]. Candidate probe sets were
selected based on p-values (,0.001) computed from 1000 random
permutations. The resulting candidate survival probe sets were
subjected to a supervised analysis [16], which comprises
computation of principal components with candidate probe sets,
Cox proportional hazards regression analysis using the resulting
principal components, and finally prognostic predictor calculation
by fitting the predictive prognosis model derived from the Cox
regression. The predictive value of the prognosis model was
evaluated by performing ‘‘leave-one-out’’ cross-validation [16,17].
Figure 1. Correlation view of 156 samples from patients with NSCLC. Pairwise correlations between any two samples are displayed, based
on 4791 informative probe sets. The colors of the cells represent Pearson’s correlation coefficient values, with deeper red indicating higher positive
and deeper blue lower negative correlations. The red diagonal line displays the self-to-self comparison of each sample. Histological classification of
the samples is depicted along the diagonal; the key to the color code is shown at the bottom. Histo-path_1 & Histo-path_2: initial and second histo-
pathological review.
doi:10.1371/journal.pone.0010312.g001
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variables, such as age, tumor cell content (%), tumor size (diameter
of tumor), smoking year, Forced Expiratory Volume 1, gender,
histology, and tumor grade was tested by the Wald test (Table S8).
The correlation between the survival signature and clinical
parameters is summarized in Table S7.
Other NSCLC classifiers
The signatures identified in this study were compared to
published histology and prognosis signatures. The tested histology
signatures were derived from Affymetrix U95A chips {[18] and
US20040241725A1}, IntelliGene chips [9], and Stanford cDNA
oligonucleotide arrays [19] (Table S9). The survival related
signatures were 20- and 6-probe set predictors developed by Lee
et al [20], one signature derived from Affymetrix U133A chips
[21], one from Affymetrix HuGeneFL chips [22,23], two from
other types of oligonucleotide array [24,25], and one from RT-
PCR assays [26] (Table S10).
Results
Study design
Tumors (n=91) and unaffected lung tissue samples (n=65)
were collected from NSCLC patients undergoing lung resection at
Erasmus MC between 1992 and 2004. The tissue specimens were
snap frozen in liquid nitrogen pre-cooled isopentane and stored in
liquid nitrogen or at 280uC until further processing. The clinical
parameters of the patients enrolled in this study are summarized in
Table 1. Paraffin sections of the tumors were scored by routine
pathology and an independent pathologist (MdB) for histo-
pathological characteristics. Eight LCC samples had a high level
of cell type heterogeneity, presenting with acinar differentiation
Figure 2. Hierarchical clustering distinguishes tumors from healthy lung tissue. A: Two-dimensional hierarchical clustering of 80 training
samples, including tumors and healthy lung samples, was performed with 187 probe sets. The relative expression to the overall mean for each probe
set (rows) in each sample (columns) is indicated by a color code. B: Hierarchical clustering of 156 tissue samples with 5 probe sets yields 2 groups,
tumor and normal lung.
doi:10.1371/journal.pone.0010312.g002
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discrepancy in histopathological classification (Table 1 and
Fig. 1), including five representing rare types of NSCLC with a
histological composition of multiple cell types. We isolated RNA
from 25 mm cryostat sections of the snap-frozen specimens and
used this for labelling and hybridisation to Affymetrix U133 2.0
plus arrays. Tumor cell content was determined from 10 mm
sections taken at the start and end of cryostat cutting. The samples
were divided into two sets, training and validation (Table 1),
according to the criteria presented in File S1, and used for the
subsequent bioinformatics analyses. By unsupervised Pearson’s
correlation analysis, tumor samples were clearly separated from
Figure 3. Clustering analysis of NSCLC tumors with the 518 probe set histology signature. A: agglomerative hierarchical clustering of 23
NSCLC samples using the 518 probe set histology signature. The relative expression to the overall mean for each probe set (rows) in each sample
(columns) is indicated by a color code. Correlation between the samples is depicted by the dendrogram. Histo-pathological diagnosis and predictions
of histology subtype by Prediction Analysis of Microarrays, using the 518 and 75 probe set signatures, are shown by colored blocks. B: correlation
dendrogram generated by agglomerative hierarchical clustering of all 91 Erasmus MC NSCLC samples using the 518 probe set signature. Histo-
pathological diagnosis of the initial and second review, and prediction of histology subtype by Prediction Analysis of Microarrays using the 518 probe
set signature, are shown by colored blocks.
doi:10.1371/journal.pone.0010312.g003
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derive a minimized signature gene set that could distinguish
tumors from healthy lung tissue.
Signature genes distinguish NSCLC from normal lung
tissue
To identify a signature gene set for NSCLC tumors, we
compared gene expression profiles from 44 tumors with that from
36 healthy lung tissues. Histology-driven analyses generated in
total 415 common probe-sets presenting differential expression in
three major types of NSCLC (data not shown). To find genes more
generally expressed by all NSCLC cases, all tumors were
compared to all healthy lung tissues without taking histological
information into account. By using different cut-offs in supervised
analysis, we identified sets of thousands to hundreds of probe-sets
characterizing NSCLC (Table S1). A final list of 187 probe sets
that were differentially expressed in all NSCLC samples was
determined as the Tumor Signature (Fig. 2A and Table S2). A
subset of these probe sets, 5 out of 187, was able to distinguish
non-cancerous tissues from malignant NSCLC with an accuracy of
98%, using Prediction Analysis of Microarrays (Fig. 2B and Table
S3). Two tumor and three non-cancerous lung tissue samples were
incorrectly classified by the optimized tumor signature. Of these,
one presented with an uncertain histological diagnosis, and two
were from patients who had developed multiple primary tumors.
We conclude that the expression signature of these 5 probe sets
accurately distinguishes NSCLC from healthy lung tissue,
regardless of NSCLC subtype.
NSCLC are sub-classified by histology signature genes.
As NSCLC are tumors with a high degree of heterogeneity, genes
characterizing histological features were identified using strictly
selected tumor samples. Firstly, the histological diagnosis had to be
consistent between the two independent pathology reviews.
Secondly, the samples should not display apparent tumor cell
heterogeneity. Thirdly, the content of cancer cells should be above
60%. We compared the gene expression profiles of each NSCLC
subtype to those of the other two subtypes, and identified a total of
518 probe sets representing the three major subtypes of NSCLC –
ADC, SCC, and LCC (Table S4). Using ‘‘leave-one-out’’ cross
validation, we found that the percentage of correct classification by
Prediction Analysis of Microarrays was 96% (22 out of 23) in the
training samples (Fig. 3A). When this signature was applied to
classify the validation samples, we found that the three carcinoid
(CAR) samples, which were not involved in deriving the signature,
and one LCC sample were separated from the other tumors by
clustering with the 518 probe sets, thus representing a unique
group (Fig. 3B). We note that the LCC sample in this group was
Figure 4. Prediction of histology subtype of Erasmus MC and Duke University NSCLC samples. A: correlation dendrogram generated by
agglomerative hierarchical clustering of all 91 Erasmus MC NSCLC samples using the 75 probe set histology signature. Histo-pathological diagnosis of
the initial and second review, and prediction of histology subtype by Prediction Analysis of Microarrays using the 75- and 518 probe set histology
signatures, are shown by colored blocks. B: correlation dendrogram generated by agglomerative hierarchical clustering of all 96 Duke University
NSCLC samples using the 75 probe set histology signature. The reported histo-pathological diagnosis, and prediction of histology subtype by
Prediction Analysis of Microarrays using the 75- and 518 probe set histology signatures, are shown by colored blocks. 75AS and 518AS: prediction
without the LCC probe sets in the histology signatures, using 68 and 329 probe sets respectively (see Tables S4 and S5).
doi:10.1371/journal.pone.0010312.g004
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signature gene set consisted of 75 probe sets (Table S5). This
optimised signature classified the training samples with 100%
accuracy (Fig. 3A). The expression profile of those genes was
applied to predict the histology subtype of the samples with
conflicting pathology diagnoses (n=18). With three exceptions, all
the ambiguously classified LCCs (n=11) were determined as ADC
or SCC by the optimized gene signature, and this was consistent
with the primary diagnosis (Fig. 4A). Of the 18 samples, one had
an ambiguous diagnosis due to unsatisfactory histology, and three
had a tumor cell content of less than 20%. We note that over 60%
(n=11) of these 18 samples presented with apparent tumor cell
type heterogeneity. Our results suggest that the 75 probe set
histology signature may aid in assigning the correct histological
classification in ambiguous cases of NSCLC.
Survival risk prediction by expression profiles
To derive prognostic information from the gene expression
profiles, we first divided NSCLC patients into groups with either
short (,2 years) or long (.5 years) overall survival. Comparing the
profiles of these two groups failed to identify any significant
differences in gene expression with a false discovery rate ,20%.
Similar negative results were obtained when the analyses were
restricted to ADC or LCC cases. A set of 29 probe sets was
identified with differential expression between SCC patients with
short- and long survival (false discovery rate ,10%; data not
shown).
Starting with the 11,515 probe sets remaining from the data
filtering process, we identified a subset of informative probe sets
that were best correlated with survival time using the Wald test
from the Cox proportional hazards model. The principal
components computed from the expression of these genes were
subjected to Cox proportional hazard regression analysis, and
built up a model for predicting a prognostic probability for each
NSCLC case. The predictive value of the prognosis model was
evaluated and optimized by performing ‘‘leave-one-out’’ cross-
validation, and resulted in an optimized model consisting of 17
probe sets. The survival signature included the EGFR gene, a
prominent gene contributing to prognosis variation in diverse
solid tumor such as breast and colorectal cancer [27,28,29,30]
(Table S6). A risk percentile cut-off of 60% was used to define
two risk groups, which were distinguished at significance
p-value=5.6E-6 by log-rank test. A Kaplan-Meier curve
of overall survival from these two risk groups is shown in
Fig. 5A.
The association between the prognosis profile and clinical
parameters was studied. The prognosis profile was significantly
associated with age (p,0.023), smoking years (p,0.014), gender
(p,0.012) and Forced Expiratory Volume 1 (p,0.009), a
parameter reflecting lung function, but not with tumor stage,
tumor cell content, tumor histology and tumor size (Table S7). We
performed multivariate proportional hazard regression analysis to
evaluate the predictive value of the prognostic predictor for patient
outcome in comparison with other clinical parameters. No
evidence of relation was found between relative hazard ratio and
age, gender, smoking year, tumor cell content, Forced Expiratory
Volume 1, tumor histology and tumor size. Table S8 shows the
Wald statistics and significance for each variable tested. Tumor
stage and the 17 probe set prognostic predictor were significantly
related to the hazard of death. However, the prognostic predictor
presented the highest importance which was 21.682 compared to
3.797 from tumor stage. Moreover the relative hazard ratio
predicted by the prognostic predictor was 2.465 (95% confidence
interval, 1.686 to 3.604, p,1.5E-06), the highest one among all
tested risks (Table 2). Similarly, the inclusion of the prognostic
predictor to the predictive model resulted in a change in model
performance of 19.5, in terms of 22 log likelihood, with a p-value
of 9.8E-06, compared to 24.3 and 2.0E-03 introduced by the
model comprising all clinical variables. Thus, the multivariate
proportional hazard analysis strongly indicates that the gene
expression profile-derived prognostic predictor is the strongest
predictor of the likelihood of death.
Validation of signature probe sets
We studied the expression patterns of all signatures in two
independent sets of microarray data collected in the United States
(US validation set), a subset of the NSCLC cohort from Duke
University (n=96) [10], and 6 normal lung specimens from
GSE3526 (NCBI GEO database). These were chosen because 1)
they were also analyzed on the Affymetrix U133 plus 2.0 arrays,
Figure 5. A 17 probe set signature predicts patient survival
time. Kaplan-Meier curves for A: 82 Erasmus MC NSCLC patients and B:
89 Duke University NSCLC patients fitted by their risk assignments
based on the 17 probe set survival signature. The high- and low-risk
groups differ significantly, indicated by the p-values. Grey bars indicate
patients at last follow-up, still alive.
doi:10.1371/journal.pone.0010312.g005
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pre-normalized data). The optimized 5 probe set tumor signature
performed on the US validation set with an accuracy of 97%: 93
out of 96 NSCLC were correctly classified as ‘tumor’ and all
normal lung specimens were correctly classified as ‘healthy’. Since
there were no LCC or other types of NSCLC in the Duke
University data set, we only used the ADC and SCC signature
probe sets, comprising 68 of the 75 probe sets in the histology
signature (Tables S4 and S5), for histological classification of the
Duke University NSCLC samples. For 84% of Duke University
samples, the prediction by the 68 probe set ADC/SCC signature
was consistent with the reported histology diagnosis. When the
LCC signature was included in the prediction analysis, this
percentage decreased to 83%: 2 samples were classified as LCC
(Fig. 4B). Follow-up data were available for 89 of 96 patients in the
Duke University cohort, and we calculated the prognostic
predictor for these patients using the 17 probe set survival
signature and the predictive model. The difference in the hazard
of death between the patient groups with a predicted good
prognosis and the group with a poor prognosis was 2.44-fold, with
a significance of p-value=1.9E-03 by log-rank test. A Kaplan-
Meier curve of overall survival is shown in Fig. 5B. If the Erasmus
MC patient cohort is combined with the cohort recruited at Duke
University, the p-value reduces to 2.6E-7 (data not shown).
Comparison with published histology and prognostic
gene expression signatures
The derived 75-probeset Histology signature was compared to
published NSCLC histology signatures (Table S9) {[6,9,18,19]
and US20040241725A1}. The largest overlap was found with
histology signature identified by Garber et al [19], 12 out of 370
genes overlapped with our 75-probeset signature.
The performance of these Histology signatures was tested with
our cohort and Duke NSCLC cohort. The correct prediction on
the EMC cohort ranged from 56% to 93% (EMC), lower than the
100% correct prediction by our signature. The best performance
from published histology signatures on the Duke cohort was 83%,
comparable to that produced by EMC Histology signature (84%).
ADC-specific signatures performed better when the aimed
aggregation was limited to two groups (ADC and non-ADC;
Table S9).
A number of gene expression profiling-derived prognostic
predictors have been previously reported for NSCLC
[20,21,22,23,24,25,26]. These signatures were derived from a
wide variety of platforms and technological approaches (Table
S10). We assessed the performance of these previously reported
prognostic signatures on the Erasmus MC and Duke University
data sets. A total of 14 signatures from 6 different publications
were tested (see File S1and Table S10 for details). For each report,
the results obtained with the signature yielding the best
stratification in low- and high risk groups are displayed in
Kaplan-Meier curves (Fig. 6 and Table S10). We find that
performance of the 6-gene signature of Boutros et al [26] was
reasonable on the Duke University cohort (p-value 0.016) but not
on the Erasmus MC cohort (p-value 0.69). The 41-gene signature
reported by Shedden et al was developed for ADC samples [21].
Performance of this signature on the complete Erasmus MC and
Duke University cohorts was unsatisfactory (p-values 0.113 and
0.158 respectively). However, if the analysis was limited to samples
classified as ADC by our histology signature, this was the only
prognostic signature that performed well on both cohorts (Erasmus
MC p-value 0.016, Duke University p-value 0.019).
The observation that our 75 probe set histology and 17 probe
set prognosis signatures perform well on independent cohorts
comprising different types of NSCLC suggests that they are robust.
Discussion
In this study, we defined a set of molecular classifiers for
NSCLC. These classifiers were developed with the Erasmus MC
cohort of NSCLC patients, and validated using the independent
US cohort. The tumor signature gene set can be used to
distinguish NSCLC from unaffected lung tissue. The histology
signature gene set may aid in the histo-pathological classification of
NSCLC in ADC, SCC and LCC. In addition, we identified a
survival signature gene set that predicts overall patient survival.
Potential for improved NSCLC classification
The unique ADC, SCC, and LCC signatures differ in the
composition of genes. The ADC signaturefavors the genes associated
with tight junction and cell adhesion molecules. In contrast, SCC
signature genes are more correlated with pathways such as cell
communication, MAPK, P53, and WNT signaling. Genes included
in the SCC signature are NKX2-1, SOX2, FGFR2/3, TP63, PI3K,
WNT5A, members of the keratin family, and genes associated with
Ras/Rho signaling pathways, such as ERBB2/3. The histological
diagnosis of LCC is based on exclusion of the other types of NSCLC.
As a result, this subtype of NSCLC is highly heterogeneous in
histopathology and clinical presentation. LCC accounts for about
Table 2. Multivariable proportional hazard analysis of the risk of death.
HAZARD RATIO Change in -2 log likelihood Significance
(95% confidence interval)
Age 1.03 (0.99–1.07) 10.35 0.001293
Tumor cell % 1.01 (0.99–1.03) 2.16 0.141500
Stage 1.32 (1.00–1.74) 3.90 0.048425
Gender 1.00 (0.44–2.27) 2.78 0.095444
Smoking years 1.00 (0.97–1.04) 1.13 0.286797
Forced Expiratory Volume 1 1.01 (0.99–1.03) 0.51 0.476836
Tumor size 1.00 (0.98–1.03) 0.00 0.979352
Histology 0.91 (0.81–1.02) 3.49 0.061814
Prognostic predictor 2.47 (1.69–3.6) 19.55 0.000010
doi:10.1371/journal.pone.0010312.t002
NSCLC Expression Profiling
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microscopy it has been shown that many cases of LCC are poorly
differentiated ADC or SCC (http://www.ncbi.nlm.nih.gov/books/
bv.fcgi?rid=cmed.section.20772). The difficulty in distinguishing
LCC from other NSCLC by routine histopathology results in
considerable variation in the classification of NSCLC cases. In
contrast, all molecularly defined NSCLC subtypes share a common
gene expression profile which is distinct from the other subtypes. For
instance, a number of well-known SCC markers, such as TP63,
PERP, Keratins, and SERPINB, were uniformly expressed among a
subset of the LCC samples, suggesting that these were actually SCC.
In addition, expression profiling revealed that some of the tumors
diagnosed as SCC display neuroendocrine characteristics, indicating
that these were neuroendocrine tumors and not classical SCC. Thus,
the molecular signatures reveal specific features of the tumors. This
could be used to improve the classification of NSCLC tumors,
especially in histologicallyheterogeneous tumors where the signatures
would identify the most characteristic molecular features of the
samples.
This 75-probe set signature conceives molecular characteristics
of three histological subtypes, ADC, SCC, and LCC. It is
outstanding in information loadage or/and robustness of aggre-
gating NSCLC subtypes than all tested published signatures
{[9,18,19] and US20040241725A1}.
A 17- probe set signature set predicts survival
We have identified a small set of survival-associated genes that is
able to predict the prognosis independent of histo-pathological
tumor type. This novel prognostic profile covers a broad range of
NSCLC subypes, and the staging of tumors used for building the
prediction model ranged from I to IV (Table 1). Multivariate
proportional hazard analysis that included age, smoking years,
gender, Forced Expiratory Volume 1, tumor stage, tumor cell
content, tumor histology, and tumor size strongly indicates that the
Figure 6. Survival prediction by published prognostic signatures. Kaplan-Meier curves for the best performing signatures (by P-value) are
shown for 82 Erasmus MC patients (left) and 89 Duke University NSCLC patients (right), fitted by their risk assignments. Grey bars indicate patients at
last follow-up, still alive. P-values are between brackets if overall survival of the low risk group is actually lower than that of the high risk group.
doi:10.1371/journal.pone.0010312.g006
Figure 7. Correlation view of Erasmus MC and Duke University NSCLC samples. In total 187 tumor samples from the Erasmus MC (n=91)
and Duke University (n=96) cohorts are shown. Pairwise correlations between any two samples are displayed, based on 3495 informative probe sets.
Histological classification of the samples, and the collection source, are depicted along the diagonal. The key to the color code is shown at the
bottom. Histo-path_E1 & Histo-path_E2: initial and second histo-pathological review of Erasmus MC samples. Histo-path_D: histo-pathological review
of Duke University samples; Histo-path_P-518 and Histo-path_P-75: predictions by PAM of histological subtypes using the 518 and 75 probe set
signatures, respectively (see Tables S4 and S5).
doi:10.1371/journal.pone.0010312.g007
NSCLC Expression Profiling
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strongest predictor of the likelihood of death. Moreover, the
performance of these molecular predictors was similar to that in
the original dataset in an independent NSCLC patient cohort,
indicating its reproducibility and potential clinical relevance. It is
possible that the aggressiveness of tumors reflected in this signature
is shared by a variety of human cancers. This small set of genes
provides potential for application with confidence and practicality
required in the clinical setting.
Divergence of prognostic gene expression signatures
Potti et al [10] developed a metagene model to predict the risk
of recurrence for individual patients. The model was predictive for
the major types of NSCLC – ADC and SCC, and performed
reasonably satisfactory in two independent patient cohorts.
Confounding components of the metagene models contain over
100 genes. These attributes complicate the direct comparison of
the metagenes to survival signatures derived from other studies. As
such, the genes in the metagene model have no predictive power
for survival prediction (data not shown).
It has been noted before that there is very little, if any, overlap
between the reported prognostic signatures for NSCLC [25,31].
Remarkably, there is not a single gene shared by the 7 signatures
tested here (the 6 best performing previously reported signatures
and the 17 probe set signature derived in this paper). This has
been attributed to the notion that the space from which such
minimized signatures can be derived is large [25,26] and hence
there are many different possible outcomes depending on the
particular dataset and bioinformatics approaches taken. In
addition, differences between patient populations with respect to
ethnic background, tumor histology, smoking status, and other
environmental factors may have an impact. For instance, outcome
signatures make predictions beyond histological subtype, but it is
still possible that genes in the signature are histology-related.
When these signatures are applied to other datasets with different
tumor composition, they do not necessarily reflect hazard of
recurrence or chance of survival. The 41-gene prognostic
signature of Shedden et al [21] was developed with ADC samples.
We found that stratification of the Erasmus MC and Duke
University cohorts by this signature is histology-dependent, since it
only performs satisfactorily on the ADC samples in these cohorts.
For this analysis, we assigned tumor types in the Erasmus MC and
Duke University cohorts with the aid of our histology signature.
Thus, a scenario emerges where application of a histology
signature is followed by analysis with a tumor type-specific
prognostic classifier. Clearly, it is important to test whether
prognostic classifiers of NSCLC are operative beyond histological
criteria.
Alternatively, prognostic classifiers transcending tumor histology
would be more straightforward to use. To develop these, different
tumor types and subtypes should be included in the experimental
set-up. Our dataset covers a relatively broad spectrum of NSCLC,
and we have validated the signatures using independent samples
profiled using the identical platform [10]. The lack of availability
of raw microarray data (.CEL files) precludes validation of our
signatures using more independent NSCLC cohorts; the complex
issue of cross-platform meta-analysis [22,32] is beyond the scope of
this paper. Nonetheless, our signatures performed well compared
to those previously reported [20,21,22,24,25,26] when tested using
the Erasmus MC and Duke University cohorts. We note that
although the Duke University samples are clearly separated from
the Erasmus MC samples in unsupervised analysis (Fig. 7) our
signatures still perform well on the Duke University data (e.g.
Figs. 4B and 5B), indicating that they are robust.
In conclusion, the sets of molecular markers identified in this
report reveal histo-pathological attributes of NSCLC. These gene
signatures might provide clinically relevant information for
NSCLC, transcending traditional histological classification and
patient outcome prediction.
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Table S1 NSCLC Tumor Signature (the longest) T:N ratio
Ratio of average expression in NSCLC samples/normal lung
tissue T mean 2log transformation of mean expression value in
NSCLC samples (average of all NSCLC and normal lung
tissue=0). N mean 2log transformation of mean expression value
in normal lung tissue samples (average of all NSCLC and normal
lung tissue=0). T SD Standard deviation of mean expression
value in NSCLC samples N SD Standard deviation of mean
expression value in normal lung tissue samples.
Found at: doi:10.1371/journal.pone.0010312.s002 (0.21 MB
XLS)
Table S2 NSCLC Tumor Signature (long) T:N ratio Ratio of
average expression in NSCLC samples/normal lung tissue T
mean 2log transformation of mean expression value in NSCLC
samples (average of all NSCLC and normal lung tissue=0). N
mean 2log transformation of mean expression value in normal
lung tissue samples (average of all NSCLC and normal lung
tissue=0). T SD Standard deviation of mean expression value in
NSCLC samples N SD Standard deviation of mean expression
value in normal lung tissue samples.
Found at: doi:10.1371/journal.pone.0010312.s003 (0.05 MB
XLS)
Table S3 NSCLC Tumor Signature (short) T:N ratio Ratio of
average expression in NSCLC samples/normal lung tissue T
mean 2log transformation of mean expression value in NSCLC
samples (average of all NSCLC and normal lung tissue=0). N
mean 2log transformation of mean expression value in normal
lung tissue samples (average of all NSCLC and normal lung
tissue=0). T SD Standard deviation of mean expression value in
NSCLC samples N SD Standard deviation of mean expression
value in normal lung tissue samples.
Found at: doi:10.1371/journal.pone.0010312.s004 (0.02 MB
XLS)
Table S4 NSCLC Histology Signature (long) ADC:OT ratio
Ratio of average expression in ADC samples/the other NSCLC
samples (SCC and LCC) SCC:OT ratio Ratio of average
expression in SCC samples/the other NSCLC samples (ADC
and LCC) LCC:OT ratio Ratio of average expression in LCC
samples/the other NSCLC samples (ADC and SCC) ADC mean
2log transformation of mean expression value in ADC samples
(average of all Erasmus MC samples=0). SCC mean 2log
transformation of mean expression value in SCC samples
(average of all Erasmus MC samples=0). LCC mean 2log
transformation of mean expression value in LCC samples
(average of all Erasmus MC samples=0). ADC SD Standard
deviation of mean expression value in ADC samples SCC SD
Standard deviation of mean expression value in SCC samples
LCC SD Standard deviation of mean expression value in LCC
samples.
Found at: doi:10.1371/journal.pone.0010312.s005 (0.15 MB
XLS)
NSCLC Expression Profiling
PLoS ONE | www.plosone.org 11 April 2010 | Volume 5 | Issue 4 | e10312Table S5 NSCLC Histology Signature (short) ADC:OT ratio
Ratio of average expression in ADC samples/the other NSCLC
samples (SCC and LCC) SCC:OT ratio Ratio of average
expression in SCC samples/the other NSCLC samples (ADC
and LCC) LCC:OT ratio Ratio of average expression in LCC
samples/the other NSCLC samples (ADC and SCC) ADC mean
2log transformation of mean expression value in ADC samples
(average of all Erasmus MC samples=0). SCC mean 2log
transformation of mean expression value in SCC samples (average
of all Erasmus MC samples=0). LCC mean 2log transformation
of mean expression value in LCC samples (average of all Erasmus
MC samples=0). ADC SD Standard deviation of mean
expression value in ADC samples SCC SD Standard deviation
of mean expression value in SCC samples LCC SD Standard
deviation of mean expression value in LCC samples.
Found at: doi:10.1371/journal.pone.0010312.s006 (0.03 MB
XLS)
Table S6 NSCLC Patient Survival Signature.
Found at: doi:10.1371/journal.pone.0010312.s007 (0.02 MB
XLS)
Table S7 Association between the prognostic predictor and
clinical parameters.
Found at: doi:10.1371/journal.pone.0010312.s008 (0.02 MB
XLS)
Table S8 Relation between variables and the relative hazard
ratio.
Found at: doi:10.1371/journal.pone.0010312.s009 (0.02 MB
XLS)
Table S9 Comparison of EMC histology signatures with other
NSCLC histology signatures.
Found at: doi:10.1371/journal.pone.0010312.s010 (0.02 MB
XLS)
Table S10 Comparison of EMC prognostic signatures with
other NSCLC prognostic signatures.
Found at: doi:10.1371/journal.pone.0010312.s011 (0.02 MB
XLS)
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